Safety and efficacy of azacitidine in myelodysplastic syndromes

PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigil, Carlos E, Martin-Santos, Taida, Garcia-Manero, Guillermo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948932/
https://www.ncbi.nlm.nih.gov/pubmed/20957213
_version_ 1782187510444589056
author Vigil, Carlos E
Martin-Santos, Taida
Garcia-Manero, Guillermo
author_facet Vigil, Carlos E
Martin-Santos, Taida
Garcia-Manero, Guillermo
author_sort Vigil, Carlos E
collection PubMed
description PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. CONCLUSION: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
format Text
id pubmed-2948932
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29489322010-10-18 Safety and efficacy of azacitidine in myelodysplastic syndromes Vigil, Carlos E Martin-Santos, Taida Garcia-Manero, Guillermo Drug Des Devel Ther Review PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. CONCLUSION: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy. Dove Medical Press 2010-09-24 /pmc/articles/PMC2948932/ /pubmed/20957213 Text en © 2010 Vigil et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Vigil, Carlos E
Martin-Santos, Taida
Garcia-Manero, Guillermo
Safety and efficacy of azacitidine in myelodysplastic syndromes
title Safety and efficacy of azacitidine in myelodysplastic syndromes
title_full Safety and efficacy of azacitidine in myelodysplastic syndromes
title_fullStr Safety and efficacy of azacitidine in myelodysplastic syndromes
title_full_unstemmed Safety and efficacy of azacitidine in myelodysplastic syndromes
title_short Safety and efficacy of azacitidine in myelodysplastic syndromes
title_sort safety and efficacy of azacitidine in myelodysplastic syndromes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948932/
https://www.ncbi.nlm.nih.gov/pubmed/20957213
work_keys_str_mv AT vigilcarlose safetyandefficacyofazacitidineinmyelodysplasticsyndromes
AT martinsantostaida safetyandefficacyofazacitidineinmyelodysplasticsyndromes
AT garciamaneroguillermo safetyandefficacyofazacitidineinmyelodysplasticsyndromes

Ejemplares similares